Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase

Oncogene

Volumn 34, Issue 3, 2015, Pages 342-350

  Xu, C ^a   Fan, C D ^a   Wang, X ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Degradation; E3 ligases; Mdm2; NEDD4 1; p53; Ubiquitination

Indexed keywords

ESCRT PROTEIN; NEDD4 UBIQUITIN PROTEIN LIGASES; PROTEIN BINDING; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE;

ANIMAL; ANIMAL EMBRYO; CELL CULTURE; CELL CYCLE CHECKPOINT; CYTOLOGY; DNA DAMAGE; FEEDBACK SYSTEM; FIBROBLAST; GENETICS; HCT116 CELL LINE; HUMAN; IMMUNOBLOTTING; JURKAT CELL LINE; KNOCKOUT MOUSE; METABOLISM; PROTEIN STABILITY; RNA INTERFERENCE; TUMOR CELL LINE; UBIQUITINATION;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELLS, CULTURED; DNA DAMAGE; EMBRYO, MAMMALIAN; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEEDBACK, PHYSIOLOGICAL; FIBROBLASTS; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; JURKAT CELLS; MICE, KNOCKOUT; PROTEIN BINDING; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84891763776     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.557     Document Type: Article

References (30)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
2. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20: 299-309.
3. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z et al. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol 2006; 26: 7269-7282.
4. Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 2009; 27: 3177-3184.
5. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995; 85: 1608-1614.
6. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ et al. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996; 87: 1155-1161.
7. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275: 8945-8951.
8. Lai Z, Ferry KV, Diamond MA, Wee KE, Kim YB, Ma J et al. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J Biol Chem 2001; 276: 31357-31367.
9. Wang X, Wang J, Jiang X. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem 286: 23725-23734.
10. Wang X, Michael D, de Murcia G, Oren M. p53 Activation by nitric oxide involves down-regulation of Mdm2. J Biol Chem 2002; 277: 15697-15702.
11. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 2004; 23: 1547-1556.
12. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer cell 2007; 12: 355-366.
13. Linares LK, Kiernan R, Triboulet R, Chable-Bessia C, Latreille D, Cuvier O et al. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 2007; 9: 331-338.
14. Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S et al. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 2010; 18: 147-159.
15. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17: 7151-7160.
16. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell 2009; 33: 275-286.
17. Mosesson Y, Chetrit D, Schley L, Berghoff J, Ziv T, Carvalho S et al. Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling. Dev Cell 2009; 16: 687-698.
18. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999; 274: 36031-36034.
19. Wang Z, Inuzuka H, Zhong J, Fukushima H, Wan L, Liu P et al. DNA damage-induced activation of ATM promotes beta-TRCP-mediated Mdm2 ubiquitination and destruction. Oncotarget 2012; 3: 1026-1035.
20. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004; 431: 873-878.
21. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121: 1085-1095.
22. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007; 128: 129-139.
23. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-smallcell lung carcinomas. Am J Pathol 2010; 177: 2622-2634.
24. Eide PW, Cekaite L, Danielsen SA, Eilertsen IA, Kjenseth A, Fykerud TA et al. NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway. Cell Signal 2013; 25: 12-18.
25. Li Q, Lozano G. Molecular pathways: targeting mdm2 and mdm4 in cancer therapy. Clin Cancer Res 2013; 19: 34-41.
26. Fan CD, Lum MA, Xu C, Black JD, Wang X. Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. J Biol Chem 2013; 288: 1674-1684.
27. Dai B, Pieper RO, Li D, Wei P, Liu M, Woo SY et al. FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res 2010; 70: 2951-2961.
28. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
29. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
30. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 2008; 15: 841-848.